Graham Boulnois

Venture Partner

Professor Graham Boulnois joined SV as a Venture Partner in 2001. He became a Partner in 2004 and then a part-time Venture Partner in 2014.

Graham has served on the Boards of numerous biotechnology companies in the UK, Sweden, Germany, Switzerland and North America as either Chairman or Non-Executive Director. These companies encompassed a broad range of therapeutic areas; they included small-molecule and antibody drug discovery and development projects, as well as drug discovery platforms.

Prior experience
Before joining SV, Graham was Senior Vice President in the R&D function at Aventis Pharma. Prior to joining Aventis, Graham spent several years at Zeneca Pharmaceuticals as Senior Vice President, Discovery Research and then with AstraZeneca Pharmaceuticals as Global Vice President, Enabling Science and Technology.
Before joining the pharmaceutical industry, he was Professor of Microbiology, Chairman of The School of Biological Sciences and Pro-Dean of the Science Faculty at Leicester University. He held the Jenner Fellowship of The Lister Institute, was a Director of the Roslin Institute and an Honorary Professor several UK Universities.

Academic credentials
BSc, Biological Sciences, PhD, Molecular Biology, University of Leicester; Fellow, The Royal Society of Biology.

Outside SV
Graham was a Director of a large acute teaching hospital, a Director of the Lister Institute and is currently Chairman of The Medicines Discovery Catapult. He is an Honorary Professor at Manchester University. Graham enjoys exploration travel and making wildlife films.

Venture Partners


Petra Thomson


Current Portfolio

Past Portfolio

Affinium Pharmaceuticals Limited
Alantos Pharmaceuticals AG
Antiva Limited (Vantia Spin-Out)
Avant Immunotherapeutics, Inc. (fka Celldex, Lorantis)
CellZome, Inc.
Delenex Therapeutics AG (Fund III)
Dynogen Pharmaceuticals, Inc.
Gyros AB
RespiVert Limited
X2 Pharma GmbH